Navigation Links
Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Date:1/13/2009

ntial growth in clinical product sales, and demand for certain products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the fact that the audit for 2008 has not yet been completed, and therefore could have audit-related adjustments; the impact of the significant global economic downturn on the company's target markets; success in increasing direct sales and the effectiveness of new sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites; changes in the protocols or levels of testing for MRSA and other Healthcare Associated Infections (HAIs); the company's ability to successfully introduce and sell products in clinical markets other than HAIs; the mix of products sold; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; unforeseen development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the company's reliance on distributors in some regions to market, sell and support its products; the impact of competitive products and pricing; and the company's ability to manage geographically-dispersed operations. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and its other reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
3. Cepheid Reports Third Quarter Revenue of $44.9 Million
4. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
5. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
6. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
9. Cepheid to Webcast Upcoming Financial Presentations
10. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
11. Cepheid Reports Second Quarter Revenue of $42.1 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... QC (PRWEB) July 10, 2014 EvoDerma ... and convenience. This rejuvenating device now comes with a second ... develops over time. , The new cup is thinner on ... design works to target rough, thin and uneven surfaces on ... firm cup for a stimulating treatment on areas such as ...
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
(Date:7/10/2014)... 2014  Kainos Capital, a firm specializing in acquiring ... it has acquired the Slim-Fast brand from Unilever. Unilever ... of the transaction were not disclosed. Slim-Fast ... that markets ready-to-drink shakes, powders, bars and snacks to ... and in the United Kingdom ...
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... Annualized Relapse Rate and was Well Tolerated in MS Patients -- PARIS, August 30, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc. (OTC Bulletin Board: GOVX ), a biotechnology ... announced the results of its Annual Shareholders Meeting, held on ... seven nominees for directors of the company to serve until ... are duly elected or appointed and qualified. They are: ...
... Bioheart, Inc., (OTC Bulletin Board: BHRT ) ... with stem cell therapy on the first two congestive ... Angeles Tijuana through its Center of Excellence, Regenerative Medicine ... an agreement to establish a Center of Excellence for ...
Cached Biology Technology:Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 2Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 3Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 4Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 5Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 6Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 7Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 8Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 9GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 2GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 3GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 4Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 2Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 3Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 4
(Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
(Date:7/11/2014)... stem cells can stimulate neurogenesis in the brain of ... and improve tissue and function injury under the condition ... therapeutic effect of adipose-derived stem cells (ADSCs) transplantation in ... injury and neurogenesis in the brain of AD mice. ... Sciences, Tsinghua University, China transplanted ADSCs into the hippocampus ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the "International Biometrics Technology Market - Industry Analysis ... report to their offering. ... attacks and crimes has created a need for high ... methods used for personnel authentication such as username and ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... ARBORA common test used to determine mercury exposure from ... the toxic metal released from fillings, according to University ... fillings slowly release mercury vapor into the mouth. But ... of whether this exposure presents a significant health risk ...
... process that releases the energy in coal without burning ... passed a milestone on the route to possible commercial use, ... Energy & Fuels describes results of a successful 200-hour ... two inexpensive but highly polluting forms of coal. ...
... 2013) - House paint containing dangerous,concentrations of lead is ... and the,company is refusing to remove the paint from ... regulations to restrict the lead content of paint in,Cameroon ... of,Occupational Knowledge International (OK International) and co-author of a ...
Cached Biology News:Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 2Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 3US company identified as manufacture of lead paint in Africa 2